MedTrace Logo

A Study of AK-01 (LY3295668) in Solid Tumors

NCT03092934 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2021-07-02

Study results available
· View outcomes & findings →

Summary

This two-part study consists of a phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either small cell lung cancer, breast cancer and/or one other solid tumor type.

Conditions

  • Neoplasms
  • Neoplasm Metastasis
  • Triple Negative Breast Neoplasms
  • Head and Neck Neoplasms
  • Breast Neoplasms
  • Solid Tumor, Adult
  • Small Cell Lung Carcinoma

Interventions

DRUG

LY3295668

Oral capsules

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-29
Primary Completion
2020-04-20
Completion
2020-04-20
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03092934 on ClinicalTrials.gov